Corcept Therapeutics | CORT - Gross Profit On Sales


Corcept Therapeutics reported $199.58M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Ardelyx USD 114.37M 8.02M Dec/2025
Assertio Holdings USD 22.24M 970K Jun/2024
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
J&J USD 16.6B 118M Dec/2025
Knight Therapeutics CAD 55.81M 10.98M Sep/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
Merck USD 13.42B 431M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 142.25M 11.34M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025